Yili Pharmaceutical Luoding Co., Ltd.

(1) To investigate the efficacy of different doses of Xiaoyinlian granules in treating acute upper respiratory tract infection (wind-heat syndrome) in children, using a placebo as a control. (2) To investigate the safety of different doses of Xiaoyinlian granules in treating acute upper respiratory tract infection (wind-heat syndrome) in children.

Omeprazole enteric-coated capsules provided by Yili Pharmaceutical (Luoding) Co., Ltd. were used as the test preparation. According to the relevant provisions of bioequivalence studies, the absorption rate and degree of the two preparations in healthy fasting human subjects were compared with those of the omeprazole enteric-coated capsules (trade name: Losec ®, reference preparation) produced by AstraZeneca AB to investigate the bioequivalence of the two preparations in humans. Secondary objective: To observe the safety of the test preparation omeprazole enteric-coated capsules and the reference preparation omeprazole enteric-coated capsules (Losec ®) in healthy subjects.

1. Primary objective: To evaluate the bioequivalence of Febuxostat Tablets (Specification: 40 mg) produced by Guangdong Yililuo Pharmaceutical Co., Ltd. and the original Febuxostat Tablets (Specification: 40 mg, trade name: Uloric®, produced by Takeda Pharmaceuticals America, Inc.) in healthy adult subjects after a single oral administration in the fed state. 2. Secondary objective: To evaluate the safety of Febuxostat Tablets in healthy adult subjects.